NaBu curtailed sorafenib resistance in HCC through epigenetic downregulation of resistance-associated microRNAs (miR-7641 and miR-199) [119]
[33] In chronic inflammatory bowel diseases, including Crohns disease, systematic reviews (including Cochrane reviews) have concluded that current randomized evidence is insufficient to support glutamine supplementation for inducing remission or modifying disease progression, and further well-powered clinical trials are required
Despite convincing data suggesting the central role of GLP-1R signalling in the food intake reduction effects of OXM, there were still some unexplained effects of the gut hormone including increased energy expenditure, suggesting a GLP-1R independent mechanism of action (35)
Patients with obesity-related heart failure, particularly HFpEF, who experience symptoms like breathlessness and reduced exercise capacity, may also benefit as emerging evidence suggests these therapies can improve symptoms and quality of life.Who should avoid them or exercise caution before use
Outcome measures include neurological severity scoring, rotarod and beam walk performance, histological assessment of lesion volume, and immunohistochemistry for axonal markers and myelin basic protein